LIVIVO - Search results -

Search results

Result 1 - 10 of total 20

Search options

Article ; Online: Advancing Inclusive Research: Establishing Collaborative Strategies to Improve Diversity in Clinical Trials.

2022 Volume 32, Issue 1, Page(s) 61–68

Abstract: Well-characterized disparities in clinical research have disproportionately affected patients of color, particularly in underserved communities. To tackle these barriers, Genentech formed the External Council for Advancing Inclusive Research, a 14-person ...

Abstract	Well-characterized disparities in clinical research have disproportionately affected patients of color, particularly in underserved communities. To tackle these barriers, Genentech formed the External Council for Advancing Inclusive Research, a 14-person committee dedicated to developing strategies to increase clinical research participation. To help improve the recruitment and retention of patients of color, this article chronicles our efforts to tangibly address the clinical research barriers at the system, study, and patient levels over the last four years. These efforts are one of the initial steps to fully realize the promise of personalized health care and provide increased patient benefit at less cost to society. Instead of simply acknowledging the problem, here we illuminate the collaborative and multilevel strategies that have been effective in delivering meaningful progress for patients.
Language	English
Publishing date	2022-01-20
Publishing country	United States
Document type	Journal Article
ZDB-ID	1274267-3
ISSN	1945-0826 ; 1049-510X
ISSN (online)	1945-0826
ISSN	1049-510X
DOI	10.18865/ed.32.1.61
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 4720: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article: Noninvasive diagnostic strategies for peripheral arterial disease.

Begelman, Susan M / Jaff, Michael R

Cleveland Clinic journal of medicine

2007 Volume 73 Suppl 4, Page(s) S22–9

Abstract: A variety of diagnostic methods for peripheral arterial disease (PAD) are available, each with strengths and limitations. The ankle-brachial index is a simple and useful screening tool for PAD that can be performed in the office setting. Segmental limb ... ...

Abstract	A variety of diagnostic methods for peripheral arterial disease (PAD) are available, each with strengths and limitations. The ankle-brachial index is a simple and useful screening tool for PAD that can be performed in the office setting. Segmental limb pressure examinations and pulse volume recordings aid in identifying the location of disease. Pulse volume recordings are especially useful, along with the ankle-brachial index, in assessing functional status during exercise. Duplex ultrasonography, magnetic resonance angiography, and computed tomographic angiography are helpful in providing anatomic detail and thus yield additional information for planning interventional therapy. Conventional angiography, the "gold standard" study for PAD diagnosis, is now usually pursued only once an intervention is planned.
MeSH term(s)	Ankle/blood supply ; Blood Pressure/physiology ; Brachial Artery/physiology ; Diagnostic Imaging ; Exercise Test ; Humans ; Peripheral Vascular Diseases/diagnosis
Language	English
Publishing date	2007-03-23
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	639116-3
ISSN	0891-1150
ISSN	0891-1150
DOI	10.3949/ccjm.73.suppl_4.s22
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ua VI Zs.212: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Clinical and Economic Burden of Commercially Insured Patients with Acromegaly in the United States: A Retrospective Analysis.

Placzek, Hilary / Xu, Yaping / Mu, Yunming / Begelman, Susan M / Fisher, Maxine

Journal of managed care & specialty pharmacy

2015 Volume 21, Issue 12, Page(s) 1106–1112

Abstract: Background: Acromegaly is a chronic disorder characterized by excess growth hormone secretion and elevated insulin-like growth factor-1 levels most often caused by a pituitary adenoma. Clinical presentation of the disease includes coarsening of the ... ...

Abstract	Background: Acromegaly is a chronic disorder characterized by excess growth hormone secretion and elevated insulin-like growth factor-1 levels most often caused by a pituitary adenoma. Clinical presentation of the disease includes coarsening of the facial features, soft-tissue swelling of the hands and feet, and overgrowth of the frontal skull and protrusion of the jaw, as well as joint symptoms. Acromegaly is associated with several comorbidities, including diabetes, cardiovascular disease, and arthropathy, which, if left untreated, can lead to early mortality. Surgery to remove the adenoma is the first-line treatment for many patients, but more than 50% of patients will require additional pharmacologic or radiation therapy. Objectives: To (a) determine the clinical and economic burden of illness among patients with acromegaly using administrative claims data from a large, commercially insured population in the United States and (b) estimate the most frequent acromegaly-related comorbidities and health care resource utilization and costs among these patients. Methods: This retrospective, observational cohort study used administrative claims data from the HealthCore Integrated Research Database, containing a geographically diverse spectrum of longitudinal claims data from the largest database of commercially insured patients in the United States. Patients were aged ≥ 20 years and fulfilled ≥ 1 of the following criteria during the intake period (March 31, 2008-July 31, 2012): ≥ 2 independent diagnostic codes for acromegaly, ≥ 1 acromegaly diagnosis code and ≥ 1 acromegaly-related procedure code, or ≥ 1 acromegaly diagnosis code and ≥ 1 medical claim for acromegaly-related therapy. The index date was defined as the date of the first medical claim for acromegaly within the intake period. Assessed outcomes included prevalence of acromegaly diagnosis and incidence of new acromegaly diagnoses during the study period (January 1, 2008-July 31, 2013), acromegaly-related comorbidities, and pharmacotherapy use. Because 2008 and 2012 data were incomplete, incidence rates were only reported for 2009, 2010, and 2011. Total and acromegaly-related health care resource utilization and annual health care costs were analyzed during a 12-month post-index observational period. Results: In total, 757 patients with acromegaly met the selection criteria for this study, with a mean age of 49.3 years (53.6% female). The total prevalence of acromegaly was 41.7 cases per million. Acromegaly incidence was 15.0, 13.3, and 9.5 cases per million in 2009, 2010, and 2011, respectively. The top 5 acromegaly-related comorbidities were hypertension, diabetes, hypothyroidism, arthropathy/arthralgia/synovitis, and sleep apnea. During the study period, 51% of patients (n = 385) used acromegaly-related pharmacologic therapy, with the most common being cabergoline and octreotide (used by 12.4% and 12.2% of patients, respectively). Overall, 18.8% of patients incurred an acromegaly-related inpatient stay; 97.0% used outpatient services other than emergency room (ER) or physician visits; 74.8% had a physician office visit; and 1.8% visited the ER for acromegaly-related reasons. In the 12-month post-index period, 37.0% of patients filed claims for acromegaly-related prescription drugs, and patients with greater than 1 claim had an average of 7.6 prescriptions. The most expensive acromegaly-related costs in this study population were inpatient hospitalizations ($6,754) and prescription drugs ($6,147). Conclusions: Consistent with previous studies, this study confirms that acromegaly is a rare condition associated with multiple comorbidities. Notably, 18.8% of this study population required an inpatient hospital admission during the 12-month post-index period, possibly because of severe comorbidities. Because acromegaly-related costs were driven by hospitalizations and pharmacotherapy, improved management of the disease may reduce the clinical and economic burden experienced by patients with acromegaly.
MeSH term(s)	Acromegaly/diagnosis ; Acromegaly/economics ; Acromegaly/epidemiology ; Acromegaly/therapy ; Adult ; Aged ; Ambulatory Care/economics ; Commerce/economics ; Comorbidity ; Databases, Factual ; Drug Costs ; Emergency Service, Hospital/economics ; Female ; Health Care Costs ; Health Resources/economics ; Health Resources/statistics & numerical data ; Hospital Costs ; Humans ; Incidence ; Insurance, Health/economics ; Male ; Middle Aged ; Office Visits/economics ; Prevalence ; Process Assessment, Health Care/economics ; Retrospective Studies ; Time Factors ; Treatment Outcome ; United States/epidemiology ; Young Adult
Language	English
Publishing date	2015-11-06
Publishing country	United States
Document type	Journal Article ; Observational Study ; Research Support, Non-U.S. Gov't
ISSN	2376-1032
ISSN (online)	2376-1032
DOI	10.18553/jmcp.2015.21.12.1106
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Manifestations of cardiac disease in carotid duplex ultrasound examination.

Madhwal, Surabhi / Yesenko, Sandra / Kim, Esther Soo Hyun / Park, Margaret / Begelman, Susan M / Gornik, Heather L

JACC. Cardiovascular imaging

2014 Volume 7, Issue 2, Page(s) 200–203

MeSH term(s)	Blood Flow Velocity ; Carotid Arteries/diagnostic imaging ; Carotid Arteries/physiopathology ; Carotid Stenosis/diagnostic imaging ; Carotid Stenosis/physiopathology ; Diagnosis, Differential ; Diagnostic Errors/prevention & control ; Echocardiography, Doppler, Color ; Echocardiography, Doppler, Pulsed ; Heart Diseases/diagnostic imaging ; Heart Diseases/physiopathology ; Heart Diseases/therapy ; Humans ; Predictive Value of Tests ; Regional Blood Flow ; Severity of Illness Index
Language	English
Publishing date	2014-02
Publishing country	United States
Document type	Case Reports ; Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	2491503-8
ISSN	1876-7591 ; 1936-878X
ISSN (online)	1876-7591
ISSN	1936-878X
DOI	10.1016/j.jcmg.2013.09.015
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 6846: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Patient-centered assessment on disease burden, quality of life, and treatment satisfaction associated with acromegaly.

Liu, Shuqian / Adelman, Daphne T / Xu, Yaping / Sisco, Jillone / Begelman, Susan M / Webb, Susan M / Badia, Xavier / Thethi, Tina K / Fonseca, Vivian / Shi, Lizheng

Journal of investigative medicine : the official publication of the American Federation for Clinical Research

2017 Volume 66, Issue 3, Page(s) 653–660

Abstract: The study aimed to assess the economic burden, health-related quality of life (HRQoL), and acromegaly treatment satisfaction in the USA. A web-based, cross-sectional survey was distributed to members of Acromegaly Community. Data related to comorbidities, ...

Abstract	The study aimed to assess the economic burden, health-related quality of life (HRQoL), and acromegaly treatment satisfaction in the USA. A web-based, cross-sectional survey was distributed to members of Acromegaly Community. Data related to comorbidities, treatment patterns, and treatment satisfaction were collected. The costs over the past 3 months included out-of-pocket cost, sick leave, leave of absence, direct loss of job due to acromegaly, unemployment, assistance to perform household chores, and family member loss of income. The HRQoL was assessed by Acromegaly Quality of Life (AcroQoL) and EQ-5D-3L questionnaires. Among 106 patients who completed the survey (mean age: 46 years, female: 76.4%), 44.3% presented with ≥5 comorbidities, and 90.6% reporting acromegaly-related symptoms. Compared with the low-symptom group 0-3 (n=41), the 4+ symptoms group (n=65) was more likely to have depression (OR=2.3, 95% CI 1.1 to 5.2) and cardiovascular disease (OR=5.8, 95% CI 2.0 to 16.7), and experienced higher costs (loss of job: $8874 vs $1717, P=0.02; unemployment disability: $17,102 vs $429, P=0.003; household chores: $2160 vs $932, P=0.0003; family members' income loss: $692 vs $122, P=0.03). The high-symptom group had lower HRQoL scores, compared with the low-symptom group (EQ-5D-3L: 0.53 vs 0.75, P<0.0001; AcroQoL: 27 vs 56, P<0.0001). Only 55.7% among patients requiring injections for acromegaly were satisfied. Patients with acromegaly who presented with multiple acromegaly-related symptoms were evidenced to have experienced higher economic burden and poorer quality of life than patients with the same diagnosis but fewer symptoms. The low rate of treatment satisfaction warrants need for further studies.
MeSH term(s)	Acromegaly/epidemiology ; Adolescent ; Adult ; Cost of Illness ; Demography ; Female ; Humans ; Male ; Middle Aged ; Patient-Centered Care ; Personal Satisfaction ; Quality of Life ; Young Adult
Language	English
Publishing date	2017-11-18
Publishing country	England
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	1217870-6
ISSN	1708-8267 ; 0009-9279 ; 1081-5589
ISSN (online)	1708-8267
ISSN	0009-9279 ; 1081-5589
DOI	10.1136/jim-2017-000570
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 307: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Patients undergoing surgical resection of primary brain tumors should receive pharmacologic venous thromboprophylaxis.

Begelman, Susan M / Green, David

The Medical clinics of North America

2003 Volume 87, Issue 6, Page(s) 1179–1187

Abstract: A 58-year-old woman presents with headache, mental status changes, and new-onset generalized seizures. MRI of the brain reveals a frontoparietal enhancing mass lesion suggestive of glioblastoma multiforme. Craniotomy for diagnosis, debulking, and likely ... ...

Abstract	A 58-year-old woman presents with headache, mental status changes, and new-onset generalized seizures. MRI of the brain reveals a frontoparietal enhancing mass lesion suggestive of glioblastoma multiforme. Craniotomy for diagnosis, debulking, and likely placement of chemotherapy-impregnated wafers is planned. Venous thromboprophylaxis is prescribed.
MeSH term(s)	Animals ; Brain Neoplasms/diagnosis ; Brain Neoplasms/drug therapy ; Brain Neoplasms/surgery ; Craniotomy ; Drug Delivery Systems ; Female ; Fibrinolytic Agents/administration & dosage ; Glioblastoma/diagnosis ; Glioblastoma/drug therapy ; Glioblastoma/surgery ; Humans ; Intraoperative Care ; Venous Thrombosis/prevention & control
Chemical Substances	Fibrinolytic Agents
Language	English
Publishing date	2003-11
Publishing country	United States
Document type	Case Reports ; Clinical Conference ; Journal Article
ZDB-ID	215710-x
ISSN	1557-9859 ; 0025-7125
ISSN (online)	1557-9859
ISSN	0025-7125
DOI	10.1016/s0025-7125(03)00105-6
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ua VI Zs.158: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Incidence of catheter-related complications in patients with central venous or hemodialysis catheters: a health care claims database analysis.

Napalkov, Pavel / Felici, Diana M / Chu, Laura K / Jacobs, Joan R / Begelman, Susan M

BMC cardiovascular disorders

2013 Volume 13, Page(s) 86

Abstract: Background: Central venous catheter (CVC) and hemodialysis (HD) catheter usage are associated with complications that occur during catheter insertion, dwell period, and removal. This study aims to identify and describe the incidence rates of catheter- ... ...

Abstract	Background: Central venous catheter (CVC) and hemodialysis (HD) catheter usage are associated with complications that occur during catheter insertion, dwell period, and removal. This study aims to identify and describe the incidence rates of catheter-related complications in a large patient population in a United States-based health care claims database after CVC or HD catheter placement. Methods: Patients in the i3 InVision DataMart® health care claims database with at least 1 CVC or HD catheter insertion claim were categorized into CVC or HD cohorts using diagnostic and procedural codes from the US Renal Data System, American College of Surgeons, and American Medical Association's Physician Performance Measures. Catheter-related complications were identified using published diagnostic and procedural codes. Incidence rates (IRs)/1000 catheter-days were calculated for complications including catheter-related bloodstream infections (CRBSIs), thrombosis, embolism, intracranial hemorrhage (ICH), major bleeding (MB), and mechanical catheter-related complications (MCRCs). Results: Thirty percent of the CVC cohort and 54% of the HD cohort had catheter placements lasting <90 days. Catheter-related complications occurred most often during the first 90 days of catheter placement. IRs were highest for CRBSIs in both cohorts (4.0 [95% CI, 3.7-4.3] and 5.1 [95% CI, 4.7-5.6], respectively). Other IRs in CVC and HD cohorts, respectively, were thrombosis, 1.3 and 0.8; MCRCs, 0.6 and 0.7; embolism, 0.4 and 0.5; MB, 0.1 and 0.3; and ICH, 0.1 in both cohorts. Patients with cancer at baseline had significantly higher IRs for CRBSIs and thrombosis than non-cancer patients. CVC or HD catheter-related complications were most frequently seen in patients 16 years or younger. Conclusions: The risk of catheter-related complications is highest during the first 90 days of catheter placement in patients with CVCs and HD catheters and in younger patients (≤16 years of age) with HD catheters. Data provided in this study can be applied toward improving patient care.
MeSH term(s)	Adolescent ; Adult ; Aged ; Catheter-Related Infections/diagnosis ; Catheter-Related Infections/epidemiology ; Central Venous Catheters/adverse effects ; Child ; Child, Preschool ; Cohort Studies ; Cross Infection/diagnosis ; Cross Infection/epidemiology ; Female ; Humans ; Incidence ; Infant ; Insurance Claim Review ; Male ; Middle Aged ; Renal Dialysis/adverse effects ; Retrospective Studies ; Thrombosis/diagnosis ; Thrombosis/epidemiology ; Young Adult
Language	English
Publishing date	2013-10-16
Publishing country	England
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	2059859-2
ISSN	1471-2261 ; 1471-2261
ISSN (online)	1471-2261
ISSN	1471-2261
DOI	10.1186/1471-2261-13-86
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Outpatient management of venous thromboembolic disease with subcutaneous lepirudin: a case report.

Begelman, Susan M / Deitcher, Steven R

Journal of thrombosis and thrombolysis

2002 Volume 13, Issue 3, Page(s) 183–185

Abstract: Outpatient treatment of deep venous thrombosis has gained widespread acceptance and is facilitated by the use of subcutaneous low molecular weight heparins (LMWH). We report two patients in whom subcutaneous lepirudin was used for long term ... ...

Abstract	Outpatient treatment of deep venous thrombosis has gained widespread acceptance and is facilitated by the use of subcutaneous low molecular weight heparins (LMWH). We report two patients in whom subcutaneous lepirudin was used for long term anticoagulation after heart transplant or surgical pulmonary embolectomy because treatment with LMWH or warfarin was contraindicated, unsuccessful, or impractical. Neither bleeding complications nor recurrent thromboses developed. Subcutaneous lepirudin may be safely and effectively employed for the outpatient treatment of venous thrombosis in selected cases including patients with heparin-induced thrombocytopenia and in those who fail LMWH.
MeSH term(s)	Adult ; Ambulatory Care/methods ; Anticoagulants/administration & dosage ; Embolectomy/adverse effects ; Heart Transplantation/adverse effects ; Hirudins/administration & dosage ; Hirudins/analogs & derivatives ; Humans ; Injections, Subcutaneous ; Male ; Postoperative Complications/drug therapy ; Postoperative Complications/prevention & control ; Pulmonary Embolism/complications ; Pulmonary Embolism/surgery ; Recombinant Proteins/administration & dosage ; Thromboembolism/drug therapy ; Thromboembolism/etiology ; Thromboembolism/prevention & control ; Treatment Outcome ; Venous Thrombosis/drug therapy ; Venous Thrombosis/etiology ; Venous Thrombosis/prevention & control
Chemical Substances	Anticoagulants ; Hirudins ; Recombinant Proteins ; lepirudin (Y43GF64R34)
Language	English
Publishing date	2002-09-27
Publishing country	Netherlands
Document type	Case Reports ; Journal Article
ZDB-ID	1230645-9
ISSN	0929-5305
ISSN	0929-5305
DOI	10.1023/a:1020435108773
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 4352: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Relationship between serum low-density lipoprotein cholesterol and in-hospital mortality following acute myocardial infarction (the lipid paradox).

Reddy, Vanessa S / Bui, Quang T / Jacobs, Joan R / Begelman, Susan M / Miller, Dave P / French, William J

The American journal of cardiology

2015 Volume 115, Issue 5, Page(s) 557–562

Abstract: Lipoprotein levels are currently recognized as independent risk factors for long-term cardiovascular events after acute myocardial infarction (AMI). During the acute-phase reaction after AMI, previous studies have reported trends of decreased low-density ...

Abstract	Lipoprotein levels are currently recognized as independent risk factors for long-term cardiovascular events after acute myocardial infarction (AMI). During the acute-phase reaction after AMI, previous studies have reported trends of decreased low-density lipoprotein cholesterol (LDL-C), increased triglycerides, and variable high-density lipoprotein cholesterol (HDL-C) levels. However, the association between LDL-C and HDL-C levels and in-hospital mortality has not been well established following AMI. The relationship between lipid levels and in-hospital all-cause mortality in 115,492 patients hospitalized for AMI (July 2002 to December 2006), registered in the National Registry of Myocardial Infarction (NRMI) 4b-5, was evaluated using multivariable-adjusted logistic regression models. Mean LDL-C was 104 ± 38, HDL-C was 41 ± 14, and triglycerides 143 ± 83 mg/dl. Compared with the lowest quartile of LDL-C (<77 mg/dl), the risk of in-hospital mortality in the second to fourth quartiles was decreased (adjusted odds ratio 0.79, 0.80, and 0.85, respectively). For HDL-C, only those in the lowest quartile (<31 mg/dl) had higher risk of in-hospital mortality (odds ratio 1.20) compared with the highest quartile (≥47 mg/dl). Results from NRMI 4b-5 suggest a lipid paradox, with lower LDL-C levels associated with increased risk of in-hospital mortality, contrary to findings outside the acute setting. Consistent with previous analyses, lowest HDL-C levels were associated with increased in-hospital mortality. In conclusion, further explorations of the relationship between very low levels of LDL-C, myocardial necrosis, and subsequent adverse cardiovascular events are warranted.
MeSH term(s)	Acute-Phase Reaction/blood ; Aged ; Aged, 80 and over ; Cholesterol, HDL/blood ; Cholesterol, LDL/blood ; Cohort Studies ; Databases, Factual ; Female ; Hospital Mortality ; Hospitalization/statistics & numerical data ; Humans ; Logistic Models ; Male ; Middle Aged ; Myocardial Infarction/blood ; Myocardial Infarction/mortality ; Risk Factors ; Triglycerides/blood ; United States
Chemical Substances	Cholesterol, HDL ; Cholesterol, LDL ; Triglycerides
Language	English
Publishing date	2015-03-01
Publishing country	United States
Document type	Journal Article
ZDB-ID	80014-4
ISSN	1879-1913 ; 0002-9149
ISSN (online)	1879-1913
ISSN	0002-9149
DOI	10.1016/j.amjcard.2014.12.006
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ui IV Zs.73: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Tenecteplase for the improvement of blood flow rate in dysfunctional hemodialysis catheters.

Goldman, Jesse / Fishbane, Steven / Oliver, Matthew J / Blaney, Martha / Jacobs, Joan R / Begelman, Susan M

Clinical nephrology

2011 Volume 77, Issue 1, Page(s) 55–61

Abstract: Background: We evaluated the efficacy and safety of the thrombolytic agent tenecteplase for the treatment of dysfunctional hemodialysis (HD) catheters.: Methods: Data were pooled from 2 Phase III clinical studies: the randomized, placebo-controlled ... ...

Abstract	Background: We evaluated the efficacy and safety of the thrombolytic agent tenecteplase for the treatment of dysfunctional hemodialysis (HD) catheters. Methods: Data were pooled from 2 Phase III clinical studies: the randomized, placebo-controlled TROPICS 3 trial and the open-label TROPICS 4 trial. Eligible patients received either an initial dose of tenecteplase (2 mg/lumen) or placebo (TROPICS 3 only) for a 1-h intracatheter dwell. Treatment success was defined as blood flow rate (BFR) ≥ 300 ml/min and a ≥ 25 ml/min increase from baseline BFR, without line reversal, 30 min before and at the end of HD. All TROPICS 4 patients and the TROPICS 3 patients enrolled after the final protocol amendment without treatment success received an instillation of tenecteplase at the end of the initial visit for an extended dwell of up to 72 h. Results: A total of 372 patients with dysfunctional catheters were enrolled in the 2 studies. Of the 297 patients treated with tenecteplase at the initial visit, 31% achieved treatment success, with a mean (SD) change from baseline BFR of 73 (120) ml/min. Among the 179 patients who received a 1-h dwell of study drug followed by extended-dwell tenecteplase, 46% had treatment success at the end of the next HD session. Six catheter-related bloodstream infections and 2 thromboses were reported in patients following tenecteplase exposure. Conclusion: Tenecteplase, administered as a 1-h dwell or a 1-h dwell followed by an extended dwell, was associated with improved BFR in dysfunctional HD catheters in the TROPICS 3 and 4 clinical trials.
MeSH term(s)	Aged ; Clinical Trials, Phase III as Topic/statistics & numerical data ; Female ; Fibrinolytic Agents/administration & dosage ; Fibrinolytic Agents/adverse effects ; Graft Occlusion, Vascular/prevention & control ; Humans ; Kidney Failure, Chronic/therapy ; Male ; Middle Aged ; Randomized Controlled Trials as Topic/statistics & numerical data ; Regional Blood Flow/drug effects ; Renal Dialysis ; Tenecteplase ; Tissue Plasminogen Activator/administration & dosage ; Tissue Plasminogen Activator/adverse effects
Chemical Substances	Fibrinolytic Agents ; Tissue Plasminogen Activator (EC 3.4.21.68) ; Tenecteplase (WGD229O42W)
Language	English
Publishing date	2011-12-15
Publishing country	Germany
Document type	Journal Article ; Meta-Analysis ; Research Support, Non-U.S. Gov't
ZDB-ID	185101-9
ISSN	0301-0430
ISSN	0301-0430
DOI	10.5414/cn1407028
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 873: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito